David Damoiseaux (D Damoiseaux)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Topics

Pluripotent Stem Cells

Chemotherapy Induced

Preterm Infants

Top Venues

Clinical pharmacokinetics

CPT: pharmacometrics & systems pharmacology

Clinical and translational science

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

David Damoiseaux, Alfred H Schinkel, Jos H Beijnen, Alwin D R Huitema, Thomas P C Dorlo
Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis. Clinical and translational science (2023)
J M Janssen, David Damoiseaux, J G C van Hasselt, F C H Amant, K van Calsteren, J H Beijnen, A D R Huitema, T P C Dorlo
Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs. Clinical pharmacokinetics (2023)
David Damoiseaux, Frédéric Amant, Jos H Beijnen, Shelby Barnett, Gareth J Veal, Alwin D R Huitema, Thomas P C Dorlo
Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk. CPT: pharmacometrics & systems pharmacology (2023)
David Damoiseaux, Daniel Centanni, Jos H Beijnen, Frédéric Amant, Alwin D R Huitema, Thomas P C Dorlo
Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach. Clinical pharmacokinetics (2023)
David Damoiseaux, Wenlong Li, Alejandra Martínez-Chávez, Jos H Beijnen, Alfred H Schinkel, Alwin D R Huitema, Thomas P C Dorlo
Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs. Pharmaceuticals (Basel, Switzerland) 15 (7) (2022)